Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

Biomarkers in outpatient heart failure management; Are they correlated to and do they influence clinical judgment?

Peeters JM, Sanders-van Wijk S, Bektas S, Knackstedt C, Rickenbacher P, Nietlispach F, Handschin R, Maeder MT, Muzzarelli SF, Pfisterer ME, Brunner-La Rocca HP.

Neth Heart J. 2014 Mar;22(3):115-21. doi: 10.1007/s12471-013-0503-y.

2.

In search of an efficient strategy to monitor disease status of chronic heart failure outpatients: added value of blood biomarkers to clinical assessment.

van Boven N, Akkerhuis KM, Anroedh SS, Battes LC, Caliskan K, Yassi W, Manintveld OC, Cornel JH, Constantinescu AA, Boersma H, Umans VA, Kardys I.

Neth Heart J. 2017 Oct 5. doi: 10.1007/s12471-017-1040-x. [Epub ahead of print]

PMID:
28983818
3.

Effects of ivabradine therapy on heart failure biomarkers.

Ordu S, Yildiz BS, Alihanoglu YI, Ozsoy A, Tosun M, Evrengul H, Kaftan HA, Ozhan H.

Cardiol J. 2015;22(5):501-9. doi: 10.5603/CJ.a2015.0012. Epub 2015 Mar 3.

PMID:
25733317
4.

N-terminal pro brain natriuretic peptide-guided management in patients with heart failure and preserved ejection fraction: findings from the Trial of Intensified versus standard medical therapy in elderly patients with congestive heart failure (TIME-CHF).

Maeder MT, Rickenbacher P, Rickli H, Abbühl H, Gutmann M, Erne P, Vuilliomenet A, Peter M, Pfisterer M, Brunner-La Rocca HP; TIME-CHF Investigators.

Eur J Heart Fail. 2013 Oct;15(10):1148-56. doi: 10.1093/eurjhf/hft076. Epub 2013 May 8.

5.

[Association of plasma amino-terminal pro-A-, B- and C-type natriuretic peptide levels with NYHA grade and echocardiographic derived parameters of cardiac function in heart failure patients].

Zhao XY, Yang YJ, Zhang J, Kang LM, Wei BQ, Gao XJ, Lü R, Zhang CL.

Zhonghua Xin Xue Guan Bing Za Zhi. 2009 Jun;37(6):486-90. Chinese.

PMID:
19927626
6.

Baseline plasma NT-proBNP and clinical characteristics: results from the irbesartan in heart failure with preserved ejection fraction trial.

McKelvie RS, Komajda M, McMurray J, Zile M, Ptaszynska A, Donovan M, Carson P, Massie BM; I-Preserve Investigators.

J Card Fail. 2010 Feb;16(2):128-34. doi: 10.1016/j.cardfail.2009.09.007. Epub 2009 Nov 4.

PMID:
20142024
7.

[Peak oxygen consumption, NT-proBNP and echocardiographic changes in patients with chronic heart failure].

Lu Z, Sun X, Hu S, Huang J.

Zhonghua Xin Xue Guan Bing Za Zhi. 2015 Mar;43(3):206-11. Chinese.

PMID:
26269338
8.

Incremental prognostic power of novel biomarkers (growth-differentiation factor-15, high-sensitivity C-reactive protein, galectin-3, and high-sensitivity troponin-T) in patients with advanced chronic heart failure.

Lok DJ, Klip IT, Lok SI, Bruggink-André de la Porte PW, Badings E, van Wijngaarden J, Voors AA, de Boer RA, van Veldhuisen DJ, van der Meer P.

Am J Cardiol. 2013 Sep 15;112(6):831-7. doi: 10.1016/j.amjcard.2013.05.013. Epub 2013 Jun 29.

PMID:
23820571
9.
10.

Circulating biomarkers of distinct pathophysiological pathways in heart failure with preserved vs. reduced left ventricular ejection fraction.

Sanders-van Wijk S, van Empel V, Davarzani N, Maeder MT, Handschin R, Pfisterer ME, Brunner-La Rocca HP; TIME-CHF investigators.

Eur J Heart Fail. 2015 Oct;17(10):1006-14. doi: 10.1002/ejhf.414. Epub 2015 Oct 16.

11.

Long-term results of intensified, N-terminal-pro-B-type natriuretic peptide-guided versus symptom-guided treatment in elderly patients with heart failure: five-year follow-up from TIME-CHF.

Sanders-van Wijk S, Maeder MT, Nietlispach F, Rickli H, Estlinbaum W, Erne P, Rickenbacher P, Peter M, Pfisterer MP, Brunner-La Rocca HP; TIME-CHF Investigators.

Circ Heart Fail. 2014 Jan;7(1):131-9. doi: 10.1161/CIRCHEARTFAILURE.113.000527. Epub 2013 Dec 18.

12.

Quality of life and chronic heart failure therapy guided by natriuretic peptides: results from the ProBNP Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) study.

Bhardwaj A, Rehman SU, Mohammed AA, Gaggin HK, Barajas L, Barajas J, Moore SA, Sullivan D, Januzzi JL.

Am Heart J. 2012 Nov;164(5):793-799.e1. doi: 10.1016/j.ahj.2012.08.015.

PMID:
23137512
13.

Role of the plasma brain natriuretic peptide in differentiating patients with congestive heart failure from other diseases.

Sirithunyanont C, Leowattana W, Sukumalchantra Y, Chaisupamonkollarp S, Watanawaroon S, Chivatanaporn B, Bhuripanyo K, Mahanonda N.

J Med Assoc Thai. 2003 May;86 Suppl 1:S87-95.

PMID:
12866774
14.

Brain natriuretic peptide and N-terminal proBNP in chronic haemodialysis patients.

Racek J, Králová H, Trefil L, Rajdl D, Eiselt J.

Nephron Clin Pract. 2006;103(4):c162-72. Epub 2006 Apr 25.

PMID:
16645318
15.

Safety and tolerability of intensified, N-terminal pro brain natriuretic peptide-guided compared with standard medical therapy in elderly patients with congestive heart failure: results from TIME-CHF.

Sanders-van Wijk S, Muzzarelli S, Neuhaus M, Kiencke S, Maeder M, Estlinbaum W, Tobler D, Mayer K, Erne P, Pfisterer ME, Brunner-La Rocca HP; TIME-CHF investigators.

Eur J Heart Fail. 2013 Aug;15(8):910-8. doi: 10.1093/eurjhf/hft079. Epub 2013 May 10.

16.

Cost-effectiveness of N-terminal pro-B-type natriuretic-guided therapy in elderly heart failure patients: results from TIME-CHF (Trial of Intensified versus Standard Medical Therapy in Elderly Patients with Congestive Heart Failure).

Sanders-van Wijk S, van Asselt AD, Rickli H, Estlinbaum W, Erne P, Rickenbacher P, Vuillomenet A, Peter M, Pfisterer ME, Brunner-La Rocca HP; TIME-CHF Investigators.

JACC Heart Fail. 2013 Feb;1(1):64-71. doi: 10.1016/j.jchf.2012.08.002. Epub 2013 Feb 4.

PMID:
24621800
17.

[Association of serum uric acid, plasma NT-proBNP, Hs-C reactive protein and invasive hemodynamic parameters in patients with heart failure].

Zhang YH, Lü R, Zhao XY, Kang LM, Yang YJ, Zhang J.

Zhonghua Xin Xue Guan Bing Za Zhi. 2009 Feb;37(2):126-9. Chinese.

PMID:
19719987
18.

Relationship between CCR and NT-proBNP in Chinese HF patients, and their correlations with severity of HF.

Lu Z, Wang B, Wang Y, Qian X, Zheng W, Wei M.

Biomed Res Int. 2014;2014:106252. doi: 10.1155/2014/106252. Epub 2014 Aug 28.

20.

Improvement in structural and functional echocardiographic parameters during chronic heart failure therapy guided by natriuretic peptides: mechanistic insights from the ProBNP Outpatient Tailored Chronic Heart Failure (PROTECT) study.

Weiner RB, Baggish AL, Chen-Tournoux A, Marshall JE, Gaggin HK, Bhardwaj A, Mohammed AA, Rehman SU, Barajas L, Barajas J, Gregory SA, Moore SA, Semigran MJ, Januzzi JL Jr.

Eur J Heart Fail. 2013 Mar;15(3):342-51. doi: 10.1093/eurjhf/hfs180. Epub 2012 Nov 6.

Supplemental Content

Support Center